Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study

  • Giuseppe Procopio (Creator)
  • Vincenzo Emanuele Chiuri (Creator)
  • Monica Giordano (Creator)
  • Giovanna Mantini (University of Rome La Sapienza) (Creator)
  • Roberto Maisano (Creator)
  • Roberto Bordonaro (Creator)
  • Nicola Calvani (Creator)
  • Gaetano Facchini (Creator)
  • Sabino De Placido (Contributor)
  • Mario Airoldi (Creator)
  • Andrea Sbrana (Creator)
  • Donatello Gasparro (Creator)
  • Giuseppe Mario Ludovico (Creator)
  • Pamela Guglielmini (Creator)
  • Emanuele Naglieri (Creator)
  • Daniele Fagnani (Creator)
  • Massimo Aglietta (Creator)
  • Luigi Schips (Creator)
  • Patrizia Beccaglia (Creator)
  • Alessandro Sciarra (Creator)
  • Lorenzo Livi (Creator)
  • Daniele Santini (Creator)

Dataset

Description

Background:Real-world data on chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited, largely deriving from small retrospective studies.Methods:ABitude is an Italian, observational, prospective, multicenter study of mCRPC patients receiving abiraterone plus prednisone in clinical practice. Chemotherapy-naïve mCRPC patients were consecutively enrolled at abiraterone start (February 2016 to June 2017) and are being followed for 3 years, with evaluation approximately every 6 months. Several clinical and patients reported outcomes were examined.Results:In this second interim analysis, among 481 enrolled patients, 453 were evaluable for analyses. At baseline, the median age was 77 years and ~69% of patients had comorbidities (mainly cardiovascular diseases). Metastases were located mainly at bones and lymph nodes; 8.4% of patients had visceral metastases. During a median follow-up of 18 months, 1- and 2-year probability of radiographic progression-free survival were 73.9% and 56.2%, respectively; the corresponding rates for overall survival were 87.3% and 70.4%. In multivariable analyses, the number of bone metastases significantly affected radiographic progression-free survival and overall survival. During abiraterone plus prednisone treatment, 65% of patients had a ⩾50% prostate-specific antigen decline, and quality of life remained appreciably high. Among symptomatic patients according to the Brief Pain Inventory) (32%), scores significantly declined after 6 months of treatment. Overall, eight patients (1.7%) had serious adverse reactions to abiraterone.Conclusions:Abiraterone plus prednisone is effective and safe for chemotherapy-naïve mCRPC patients in clinical practice.
Dati resi disponibili2020
EditoreSAGE Journals

Cita questo